C3 GLOMERULOPATHY
Clinical trials for C3 GLOMERULOPATHY explained in plain language.
Never miss a new study
Get alerted when new C3 GLOMERULOPATHY trials appear
Sign up with your email to follow new studies for C3 GLOMERULOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare kidney disease: experimental drug NM8074 enters human trials
Disease control Not yet recruitingThis early-stage trial tests a new drug, NM8074, in 18 adults with C3 glomerulopathy, a rare kidney disease where the immune system attacks the kidneys. The goal is to see if the drug is safe and can reduce protein leakage into urine, a sign of kidney damage. Participants will re…
Matched conditions: C3 GLOMERULOPATHY
Phase: PHASE1, PHASE2 • Sponsor: NovelMed Therapeutics • Aim: Disease control
Last updated May 15, 2026 12:07 UTC
-
New study tracks Fabhalta's Real-World safety for rare blood and kidney diseases
Disease control Not yet recruitingThis study is a post-marketing surveillance of Fabhalta (iptacopan) in Korean adults with paroxysmal nocturnal hemoglobinuria (PNH) or C3 glomerulopathy (C3G). It aims to track side effects and how well the drug works in everyday medical practice. About 21 participants will be ob…
Matched conditions: C3 GLOMERULOPATHY
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 05, 2026 11:53 UTC
-
New study to analyze Real-World use of iptacopan for rare kidney disease
Knowledge-focused Not yet recruitingThis study looks at medical records of 83 adults with C3 glomerulopathy (a rare kidney disease) who are taking the drug iptacopan. Researchers will describe patients' health history, lab results, and how their disease changes over a year. The goal is to learn more about the types…
Matched conditions: C3 GLOMERULOPATHY
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated May 13, 2026 16:01 UTC